1. Home
  2. OBDE vs NVAX Comparison

OBDE vs NVAX Comparison

Compare OBDE & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OBDE
  • NVAX
  • Stock Information
  • Founded
  • OBDE 2020
  • NVAX 1987
  • Country
  • OBDE United States
  • NVAX United States
  • Employees
  • OBDE N/A
  • NVAX N/A
  • Industry
  • OBDE
  • NVAX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • OBDE
  • NVAX Health Care
  • Exchange
  • OBDE NYSE
  • NVAX Nasdaq
  • Market Cap
  • OBDE 1.8B
  • NVAX 2.0B
  • IPO Year
  • OBDE N/A
  • NVAX 1995
  • Fundamental
  • Price
  • OBDE $14.55
  • NVAX $9.76
  • Analyst Decision
  • OBDE Buy
  • NVAX Buy
  • Analyst Count
  • OBDE 1
  • NVAX 6
  • Target Price
  • OBDE $16.00
  • NVAX $17.83
  • AVG Volume (30 Days)
  • OBDE 180.0K
  • NVAX 7.2M
  • Earning Date
  • OBDE 11-06-2024
  • NVAX 11-07-2024
  • Dividend Yield
  • OBDE 4.03%
  • NVAX N/A
  • EPS Growth
  • OBDE N/A
  • NVAX N/A
  • EPS
  • OBDE N/A
  • NVAX N/A
  • Revenue
  • OBDE N/A
  • NVAX $987,667,000.00
  • Revenue This Year
  • OBDE N/A
  • NVAX N/A
  • Revenue Next Year
  • OBDE N/A
  • NVAX N/A
  • P/E Ratio
  • OBDE N/A
  • NVAX N/A
  • Revenue Growth
  • OBDE N/A
  • NVAX N/A
  • 52 Week Low
  • OBDE $13.60
  • NVAX $3.53
  • 52 Week High
  • OBDE $16.80
  • NVAX $23.86
  • Technical
  • Relative Strength Index (RSI)
  • OBDE 55.89
  • NVAX 36.20
  • Support Level
  • OBDE $14.16
  • NVAX $9.52
  • Resistance Level
  • OBDE $14.65
  • NVAX $10.63
  • Average True Range (ATR)
  • OBDE 0.20
  • NVAX 0.57
  • MACD
  • OBDE 0.01
  • NVAX -0.12
  • Stochastic Oscillator
  • OBDE 80.33
  • NVAX 9.97

About OBDE BLUE OWL CAPITAL CORP III

Blue Owl Capital Corp III is focused on originating and making loans to, and debt and equity investments in middle-market companies based predominantly in the United States. Its objective is to generate current income and, to a lesser extent, capital appreciation by targeting investment opportunities with favorable risk-adjusted returns. The company invests in senior secured or unsecured loans, subordinated loans or mezzanine loans and, to a lesser extent, equity and equity-related securities including warrants, preferred stock and similar forms of senior equity, which may or may not be convertible into a portfolio company's common equity.

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.

Share on Social Networks: